877133-56-7

Basic information

• Product Name: 2-chloro-5-(MethoxyMethoxy)pyridine
• Synonyms: 2-chloro-5-(MethoxyMethoxy)pyridine
• CAS NO: 877133-56-7
• Molecular Formula: C₇H₈ClNO₂
• Molecular Weight: 173.59692
• EINECS: -0
• Mol File: 877133-56-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-chloro-5-(MethoxyMethoxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-(MethoxyMethoxy)pyridine(877133-56-7)
• EPA Substance Registry System: 2-chloro-5-(MethoxyMethoxy)pyridine(877133-56-7)

Safety Data

• Hazardous Substances Data: 877133-56-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-chloro-5-(MethoxyMethoxy)pyridine is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its unique structure allows for the potential enhancement of drug efficacy and selectivity, making it a valuable component in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 2-chloro-5-(MethoxyMethoxy)pyridine is utilized as a precursor in the synthesis of crop protection agents. Its functional groups can be tailored to create novel agrochemicals with improved performance and selectivity in pest and disease control.
Used in Organic Synthesis:
2-chloro-5-(MethoxyMethoxy)pyridine is used as a versatile starting material in organic synthesis. Its chlorinated and methoxymethoxy functional groups provide a foundation for the development of a wide range of novel chemicals and materials, contributing to advancements in various chemical disciplines.

Upstream product

• 41288-96-4 6-chloropyridine-3-ol 
• 107-30-2 chloromethyl methyl ether 
• 13057-17-5 bromethyl methyl ether 

Downstream Products

• 915207-10-2 4-(5-methoxymethoxypyridin-2-yl)piperazine-1-carboxylic acid benzyl ester 
• 861966-16-7 4-(5-hydroxypyridin-2-yl)piperazine-1-carboxylic acid benzyl ester 
• 877133-57-8 2-chloro-4-iodo-5-(methoxymethoxy)pyridine 
• 877133-58-9 6-chloro-4-iodo-pyridin-3-ol 
• 1211516-07-2 2-chloro-4-iodo-5-methoxy-pyridine 
• 1441754-60-4 5-(2-chloro-5-methoxy-pyridin-4-yl)-4-(4-chloro-2-methyl-phenyl)-3-isopropyl-2-(2-methoxy-phenyl)-4,5-dihydro-2H-pyrrolo[3,4-c]pyrazol-6-one 
• 1060804-53-6 2-chloro-5-hydroxypyridine-4-carbaldehyde 
• 1315362-16-3 methyl 5-chlorofuro[2.3-c]pyridine-2-carboxylate 
• 1454285-47-2 5-chlorofuro[2,3-c]pyridine-2-carboxylic acid 
• 1454285-48-3 N-[[4-(benzenesulfonyl)phenyl]methyl]-5-chlorofuro[2,3-c]pyridine-2-carboxamide 
• 1454285-49-4 N-[[4-(benzenesulfonyl)phenyl]methyl]-5-[(diphenylmethylidene)amino]furo[2.3-c]pyridine-2-carboxamide 
• 1454285-13-2 5-amino-N-[[4-(benzenesulfonyl)phenyl]methyl]furo[2,3-c]pyridine-2-carboxamide 
• 1606121-70-3 (2-(3-fluorophenyl)-5-hydroxypyridin-4-yl)boronic acid 
• 1606121-69-0 2-(3-fluorophenyl)-5-(methoxymethoxy)pyridine 

Relevant articles and documents

TETRAHYDROBENZO-QUINOLINE SULFONAMIDES DERIVATIVE COMPOUNDS

The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses,

DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS

The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FcεRI receptor.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR

Disclosed are heterocyclic compounds as inhibitors of FGFR-4 represented by formula (I). Also disclosed is a pharmaceutical composition that includes an inhibitor of FGFR-4. The compounds maybe used to treat diseases mediated with abnormality of FGFR-4 and /or FGF19, such as hepatocellular carcinoma and other forms of cancer.

Heterocyclic compound as FGFR inhibitor, synthesis method and applications thereof

The present invention discloses a heterocyclic compound as an FGFR inhibitor, and a synthesis method thereof, and applications of the heterocyclic compound in preparation of drugs for treating cancers. According to the present invention, the heterocyclic compound as the FGFR inhibitor or the pharmaceutically acceptable salt thereof has high FGFR inhibitory action, and the pharmaceutical composition prepared from the heterocyclic compound has good anticancer effect and wide application range.

CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS

There is provided compounds of formula I, (I) wherein R1, R2, R3 R4, R5, R6, R7a and R7b have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. CDK8 and/or Haspin kinase) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS

The invention is concerned with the compounds of formula I and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.

Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors

NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moieties also led to consistent and potent inhibition of CYP2C9. In an attempt to reduce CYP2C9 inhibition, a parallel synthesis approach was used to identify central benzyl group replacements with increased Fsp3. A spirocyclic central motif was thus discovered that was combined with left-hand pyridines (or pyridine-like systems) to provide cellularly potent NAMPT inhibitors with minimal CYP2C9 inhibition. Further optimization of potency and ADME properties led to the discovery of compound 68, a highly potent NAMPT inhibitor with outstanding efficacy in a mouse tumor xenograft model and lacking measurable CYP2C9 inhibition at the concentrations tested.

COMPOUNDS AND METHODS OF USE

This disclosure provides compounds and compositions and methods of using those compounds and compositions to treat diseases and disorders associated with excessive transforming growth factor-beta (TGFβ) activity. This disclosure also provides methods of using the compounds in combination with one or more cancer immunotherapies.